When will this stock get the exposure it deserves, by all metrics it is undervalued, the NPAT of 1.5m last year and huge debt paydown means this company will have to break out sooner or later. The Morningstar analysis of this stock doesn't do it justice in terms of valuation. Undervalued, should be trading at 4 cents.
Will be bought out if company isn't careful, as happened to the other pharma stock listed in the article above, trading at well below revenue multiples.
FY19 outlook
• Increase in multi year supply contracts with power & road authorities and municipality's
• FY19 tracking to deliver double digit revenue & earnings growth on an underlying basis
• Continual drive on “diversification revenue program” from:
Ø Smart City - Software Platform “TST”.
Ø IoT applications for road authorities and municipalities.
Ø LED street and road lighting.
Ø Installation & term maintenance contracts.
Ø Export markets: UK, South America, Middle East, Asia.
